Carbonic Anhydrase 1 Inhibitors for Selective Mast Cell Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are limited treatment options for mast cell-related diseases such as allergic inflammation, mastocytosis, and mast cell activation syndrome, with existing carbonic anhydrase inhibitors having significant side effects and suboptimal potency and selectivity.
Innovation Solution
Development of novel carbonic anhydrase inhibitors, specifically targeting Carbonic anhydrase 1, to inhibit mast cell development and inflammation, including compounds of Formula I and Formula A, which can be administered to treat conditions mediated by carbonic anhydrase enzymes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing carbonic anhydrase inhibitors are used to treat mast cell-related diseases, then some therapeutic effect is achieved, but the potency and selectivity are suboptimal and significant side effects occur
Solution Approach 1:
The patent modifies the chemical structure of carbonic anhydrase inhibitors by changing parameters such as substituting different aromatic groups (aryl, heteroaryl), varying alkyl chain lengths, and introducing different functional groups (sulfonamide, carboxylate, carbonate esters). These parameter changes in the molecular structure enable improved potency and selectivity against Carbonic anhydrase 1 while reducing side effects associated with existing inhibitors.
Solution Approach 2:
The patent focuses on developing inhibitors with specific local structural features that target Carbonic anhydrase 1 expressed on mast cell surfaces. By designing molecules with particular substitution patterns and functional group arrangements at specific positions, the inhibitors achieve localized interaction with the enzyme's active site, enhancing selectivity and reducing off-target effects.
2Reliability
If higher doses of existing carbonic anhydrase inhibitors are administered to improve therapeutic effect, then mast cell development and inflammation are inhibited, but side effects increase
Solution Approach 1:
The patent achieves enhanced potency through parameter changes in molecular structure, allowing effective inhibition of mast cell responses at lower doses. The modified structures with specific aromatic substitutions and functional groups increase binding affinity to Carbonic anhydrase 1, thereby reducing the required dosage and associated side effects.
3Reliability
If novel carbonic anhydrase inhibitors with improved potency and selectivity are developed, then therapeutic benefits increase, but the complexity of compound structure increases
Solution Approach 1:
The patent systematically varies structural parameters within defined classes of compounds (Formula I and Formula A), exploring different aromatic substitutions, chain lengths, and functional groups. This structured approach to parameter changes enables identification of optimal structures with improved potency and selectivity while maintaining reasonable structural complexity for drug development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel carbonic anhydrase inhibitors effectively inhibit mast cell responses and inflammation, offering improved potency and selectivity compared to existing inhibitors, providing therapeutic benefits for mast cell-related diseases.
Implementation Method 1
Carbonic anhydrase enzyme inhibitors and methods of use thereof
Data Source
AI summary
Provided herein are novel compounds, such as a compound of Formula I or Formula A: or a salt thereof, wherein R1-R3, L1, R10, ring A and ring B have any of the values described in the specification, as well as compositions comprising the novel compounds herein. The compounds are typically carbonic anhydrase inhibitors and are useful for the prophylactic or therapeutic treatment of a disease or condition mediated by a carbonic anhydrase enzyme.